Opportunity Information: Apply for PAR 16 016
Apply for PAR 16 016
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Novel Genomic Technology Development (R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172,.
- This funding opportunity was created on Oct 27, 2015 and posted on Oct 27, 2015.
- Applicants must submit their applications by Jan 11, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Novel Genomic Technology Development (R43/R44) opportunity, published by the National Institutes of Health (HHS-NIH), is a Small Business Innovation Research (SBIR) grant program designed to push genomics forward through new technology development. It is listed as a discretionary grant under Funding Opportunity Number PAR 16-016 and is associated with CFDA numbers 93.172 (and also references 93). The focus is explicitly on technology innovation in genomics that goes beyond building the next generation of nucleic acid sequencing platforms, meaning proposals should target other parts of the genomics toolchain where breakthroughs could unlock new biological insight or enable capabilities that are not currently practical.
At its core, the program is trying to catalyze major advances by supporting very novel, high-impact ideas from small businesses, with the expectation that the resulting technologies could substantially influence the field within a three-to-five-year window. That time horizon matters because it signals an emphasis on ambitious but still realistically translatable development work: not just incremental improvements, and not purely academic exploration, but technology creation that could meaningfully change what researchers or clinicians can do in the near term. In practice, that could include new methods for measuring genomic function, mapping genome organization, interpreting variation, improving sample preparation, enhancing sensitivity or throughput of non-sequencing assays, enabling better single-cell or spatial genomic analyses, or creating platforms and workflows that make genomics more accessible, accurate, scalable, or informative. The FOA is intentionally broad across the "gamut of genomics technology development," which is another way of saying NIH is open to a wide range of approaches as long as the technology is truly enabling and has a clear path to strong impact.
Eligibility is limited to small businesses, consistent with SBIR requirements, and the funding mechanism is R43/R44, which corresponds to the SBIR phased structure (Phase I and Phase II). While the excerpt does not list an award ceiling or expected number of awards, the intent is clear: to provide a support mechanism that helps small companies de-risk early development and move novel genomics technologies toward practical demonstration and adoption. The opportunity was created and posted on October 27, 2015, and the listed closing date was January 11, 2018 (both original and current closing dates match), indicating a defined submission window for that cycle of the announcement.
Frequently Asked Questions (FAQs): Novel Genomic Technology Development (R43/R44) - SBIR (PAR 16-016)
1) What is the Novel Genomic Technology Development (R43/R44) opportunity?
This is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) funding opportunity focused on developing novel, high-impact genomics technologies. It is intended to help small businesses create enabling tools and methods that can substantially move the field forward.
2) Which federal agency is offering this grant?
The opportunity is published by the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH).
3) What is the Funding Opportunity Number (FOA) for this program?
The Funding Opportunity Number is PAR 16-016.
4) What type of grant is this?
It is listed as a discretionary grant and uses the SBIR R43/R44 mechanisms, which are the standard SBIR Phase I and Phase II structure.
5) What do R43 and R44 mean in this context?
R43 and R44 refer to the SBIR phased award structure. R43 corresponds to SBIR Phase I and R44 corresponds to SBIR Phase II. The program is designed to support early development (Phase I) and continued development/demonstration (Phase II) of promising technologies.
6) Who is eligible to apply?
Eligibility is limited to small businesses, consistent with SBIR program requirements.
7) What is the main goal of this SBIR opportunity?
The core goal is to catalyze major advances in genomics by supporting very novel technology development ideas from small businesses, with the expectation that successful technologies could substantially influence genomics within a three-to-five-year window.
8) What kinds of projects are NIH looking for under this FOA?
The focus is on technology innovation across the genomics toolchain that could unlock new biological insight or enable capabilities that are not currently practical. The scope is intentionally broad as long as the technology is truly enabling and has a clear path to strong impact.
9) Are next-generation nucleic acid sequencing platforms a fit for this program?
The program explicitly emphasizes innovations that go beyond building the next generation of nucleic acid sequencing platforms. Proposed work should target other parts of the genomics toolchain where breakthroughs could be enabling.
10) What parts of the genomics toolchain could be relevant (examples mentioned in the description)?
Examples described include new methods for measuring genomic function, mapping genome organization, interpreting genomic variation, improving sample preparation, enhancing sensitivity or throughput of non-sequencing assays, enabling better single-cell or spatial genomic analyses, and creating platforms/workflows that make genomics more accessible, accurate, scalable, or informative.
11) Is the FOA narrowly defined or broad?
It is intentionally broad across the "gamut of genomics technology development," meaning NIH is open to a wide range of approaches as long as they represent truly novel, enabling technology with a credible path to high impact.
12) What does the three-to-five-year impact horizon imply?
It signals an emphasis on ambitious but realistically translatable development work: not incremental tweaks and not purely academic exploration, but technology creation that could meaningfully change what researchers or clinicians can do in the near term.
13) Is this funding meant to help reduce early technical or commercialization risk?
Yes. The stated intent is to provide a support mechanism that helps small companies de-risk early development and move novel genomics technologies toward practical demonstration and adoption.
14) Does the provided information list an award ceiling or the expected number of awards?
No. The excerpt does not provide an award ceiling or an expected number of awards.
15) What CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA 93.172 and also references 93.
16) When was this opportunity created and posted?
It was created and posted on October 27, 2015.
17) What was the closing date listed for this opportunity?
The listed closing date was January 11, 2018. The information provided indicates the original and current closing dates match.
18) Does the provided information indicate multiple cycles or an ongoing submission window?
No. Based on the information provided, it reflects a defined submission window for that cycle of the announcement, with the closing date shown as January 11, 2018.
19) What is the key differentiator NIH seems to be prioritizing?
NIH appears to prioritize truly novel, enabling genomics technology development that can deliver major advances, rather than incremental improvements or proposals centered on building the next generation of sequencing platforms.
20) What is the intended outcome if a project is successful?
The intended outcome is a new genomics technology that moves beyond early concept and toward practical demonstration and adoption, with the potential to substantially influence the field within three to five years.
Browse more opportunities from the same agency: HHS-NIH11
Browse more opportunities from the same category: Health
Next opportunity: BRAIN Initiative: Non-Invasive Neuromodulation - Mechanisms and Dose/Response Relationships for Targeted CNS Effects (R01)
Previous opportunity: Increasing Access to Medication-Assisted Treatment (MAT) in Rural Primary Care Practices (R18)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 016
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 016) also looked into and applied for these:
| Funding Opportunity |
|---|
| Planning Grant for Emerging Epidemic Virus Research Training for West African Countries with Widespread Transmission of Ebola- Guinea, Liberia, and Sierra Leone (D71) Apply for PAR 16 045 Funding Number: PAR 16 045 Agency: HHS-NIH11 Category: Health Funding Amount: $50,000 |
| Strengthening Care and Support Services for Orphans and Vulnerable Children and their Families, plus HIV Prevention for Youth in the Republic of Côte d’Ivoire Under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10290501SUPP16 Funding Number: CDC RFA PS10 10290501SUPP16 Agency: HHS-CDC Category: Health Funding Amount: $4,312,949 |
| Grants to Expand Care Coordination Targeted Capacity Expansion (TCE) through the Use of Technology Assisted Care (TAC) in Targeted Areas of Need (Short Title: TCE-TAC) Apply for TI 16 001 Funding Number: TI 16 001 Agency: HHS-SAMHS Category: Health Funding Amount: $280,000 |
| Licensure Portability Grant Program Apply for HRSA 16 014 Funding Number: HRSA 16 014 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Nutrition Strategies to Address Micronutrient Deficiencies Apply for CDC RFA DP16 1603 Funding Number: CDC RFA DP16 1603 Agency: HHS-CDC-NCCDPHP Category: Health Funding Amount: $1,000,000 |
| Precision Medicine Initiative Cohort Program Coordinating Center (U2C) Apply for RFA PM 16 001 Funding Number: RFA PM 16 001 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| PEPFAR Small Grants Program 2015-2016, U.S. Embassy Maseru Apply for DOS MSU PFSGP FY16 Funding Number: DOS MSU PFSGP FY16 Agency: DOS-MLS Category: Health Funding Amount: $25,000 |
| National Foundation for the Centers for Disease Control and Prevention Apply for CDC RFA CD16 1601 Funding Number: CDC RFA CD16 1601 Agency: HHS-CDC-OD Category: Health Funding Amount: $1,250,000 |
| Reinforcing HIV Clinical Services within a Network of Faith-based Health Institutions in Haiti under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1710 Funding Number: CDC RFA GH16 1710 Agency: HHS-CDC-CGH Category: Health Funding Amount: $5,500,000 |
| Pediatric Diagnostic Biomarkers for Active Pulmonary TB Disease (R01) Apply for RFA AI 15 057 Funding Number: RFA AI 15 057 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Building Health Sector Capacity for HIV/AIDS Prevention, Care, and Treatment Interventions and Coordination in the Republic of Côte d’Ivoire under the President’s Emergency Plan for AIDS Relief Apply for CDC RFA PS10 10360501SUPP16 Funding Number: CDC RFA PS10 10360501SUPP16 Agency: HHS-CDC Category: Health Funding Amount: $1,088,129 |
| HIV/AIDS Vaccine Scholars Program (K01) Apply for PAR 16 028 Funding Number: PAR 16 028 Agency: HHS-NIH11 Category: Health Funding Amount: $350,000 |
| NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35) Apply for RFA DE 17 002 Funding Number: RFA DE 17 002 Agency: HHS-NIH11 Category: Health Funding Amount: $650,000 |
| Maternal, Infant and Early Childhood Home Visiting Program - Formula Apply for HRSA 16 172 Funding Number: HRSA 16 172 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01) Apply for PAR 16 020 Funding Number: PAR 16 020 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Conducting Public Health Research in Thailand: technical collaboration with the Ministry of Public Health in the Kingdom of Thailand (MOPH) Apply for RFA GH 16 003 Funding Number: RFA GH 16 003 Agency: HHS-CDC-HHSCDCERA Category: Health Funding Amount: $7,000,000 |
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76) Apply for RFA AG 16 023 Funding Number: RFA AG 16 023 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Fogarty Global Injury and Trauma Research Training Program (D43) Apply for RFA TW 16 001 Funding Number: RFA TW 16 001 Agency: HHS-NIH11 Category: Health Funding Amount: $250,000 |
| Conducting Public Health Research through Field Epidemiology and Laboratory Training Programs Apply for RFA GH 11 00105CONT16 Funding Number: RFA GH 11 00105CONT16 Agency: HHS-CDC-HHSCDCERA Category: Health Funding Amount: Case Dependent |
| MCH Research Network on Promoting Healthy Weight among Children with Autism Spectrum Disorder and other Developmental Disabilities Apply for HRSA 16 044 Funding Number: HRSA 16 044 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 016", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.